Recent submissions
Now showing items 641-660 of 4698
-
Exploring an oncolytic virus triggered PD-L1 response via immunoPET
(Institute of Cancer Research (University Of London), 2023-01-23)Oncolytic virotherapy (OV) exploits viruses which preferentially infect and kill cancerous cells. Moreover, oncolytic viruses stimulate the tumour-immune microenvironment towards an inflammatory phenotype. Therefore, OV ... -
Surgeon-led multi-centre collaborative research in head and neck cancer : studies in remote triage, transoral robotic surgery for recurrent disease and consensus management in unknown primary disease
(Institute of Cancer Research (University Of London), 2023-01-23)Head and neck cancer (HNC) is newly diagnosed in around 1.5 million people each year, making it the sixth most common type of cancer worldwide. Some elements of HNC care are common and can be adequately investigated in a ... -
Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma.
(AMER ASSOC CANCER RESEARCH, 2023-02-01)Although the 5-year survival rates for sarcoma patients have improved, the proportion of patients relapsing after first-line treatment remains high, and the survival of patients with metastatic disease is dismal. Moreover, ... -
EROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling.
(eLIFE SCIENCES PUBL LTD, 2022-11-24)EROS (essential for reactive oxygen species) protein is indispensable for expression of gp91phox, the catalytic core of the phagocyte NADPH oxidase. EROS deficiency in humans is a novel cause of the severe immunodeficiency, ... -
Identifying and characterising Thrap3, Bclaf1 and Erh interactions using cross-linking mass spectrometry.
(F1000 Research Ltd, 2021-01-01)Background: Cross-linking mass spectrometry (XL-MS) is a powerful technology capable of yielding structural insights across the complex cellular protein interaction network. However, up to date most of the studies utilising ... -
Candida albicans Hyphal Extracellular Vesicles Are Different from Yeast Ones, Carrying an Active Proteasome Complex and Showing a Different Role in Host Immune Response.
(AMER SOC MICROBIOLOGY, 2022-06-29)Candida albicans is the principal causative agent of lethal fungal infections, predominantly in immunocompromised hosts. Extracellular vesicles (EVs) have been described as crucial in the interaction of microorganisms with ... -
Nbeal2 interacts with Dock7, Sec16a, and Vac14.
(AMER SOC HEMATOLOGY, 2018-03-01)Mutations in NBEAL2, the gene encoding the scaffolding protein Nbeal2, are causal of gray platelet syndrome (GPS), a rare recessive bleeding disorder characterized by platelets lacking α-granules and progressive marrow ... -
ROS Dynamics Delineate Functional States of Hippocampal Neural Stem Cells and Link to Their Activity-Dependent Exit from Quiescence.
(CELL PRESS, 2021-02-04)Cellular redox states regulate the balance between stem cell maintenance and activation. Increased levels of intracellular reactive oxygen species (ROS) are linked to proliferation and lineage specification. In contrast ... -
Efficient and gentle delivery of molecules into cells with different elasticity via Progressive Mechanoporation.
(ROYAL SOC CHEMISTRY, 2021-06-15)Intracellular delivery of cargo molecules such as membrane-impermeable proteins or drugs is crucial for cell treatment in biological and medical applications. Recently, microfluidic mechanoporation techniques have enabled ... -
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
(ELSEVIER, 2023-02-01)BACKGROUND: Protein markers of cellular proliferation, hypoxia, apoptosis, cell cycle checkpoints, growth factor signalling and inflammation in localised prostate tumours have previously shown prognostic ability. A ... -
Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.
(ELSEVIER SCIENCE LONDON, 2023-05-01)AIMS: To evaluate whether there is sufficient correlation between patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) in bladder cancer follow-up post-radiotherapy to streamline data collection and to ... -
Understanding the Benefit of Magnetic Resonance-guided Adaptive Radiotherapy in Rectal Cancer Patients: a Single-centre Study.
(ELSEVIER SCIENCE LONDON, 2022-11-03)AIMS: Neoadjuvant chemoradiotherapy followed by surgery is the mainstay of treatment for patients with rectal cancer. Standard clinical target volume (CTV) to planning target volume (PTV) margins of 10 mm are used to ... -
SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy.
(OXFORD UNIV PRESS, 2022-11-07)INTRODUCTION: Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer ... -
A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules.
(ELSEVIER, 2022-12-01)BACKGROUND: Large lung nodules (≥15 mm) have the highest risk of malignancy, and may exhibit important differences in phenotypic or clinical characteristics to their smaller counterparts. Existing risk models do not stratify ... -
The role of cancer-associated fibroblasts in altering signal transduction and drug resistance in KRAS mutated cancers
(Institute of Cancer Research (University Of London), 2023-01-04)KRAS is commonly mutated in solid tumours but effective treatment is limited due to resistance. Cancer-associated fibroblasts (CAFs) are a key tumour microenvironment component but how it interacts with KRAS mutant-cancer ... -
The comprehensive proteomic characterisation of soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2023-01-04)Soft tissue sarcomas (STS) are a group of rare and heterogeneous mesenchymal malignancies. The extensive clinical and biological heterogeneity of STS complicates clinical disease management, and in the advanced setting ... -
'You give me fever!': are health services ready for immune cell engager therapy in advanced solid malignancies?
(BMJ PUBLISHING GROUP, 2022-12-01)Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets ... -
Systemic Therapy for Hereditary Breast Cancers.
(W B SAUNDERS CO-ELSEVIER INC, 2023-02-01)Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we discuss systemic treatment ...